

AD_____

AWARD NUMBER DAMD17-98-1-8118

TITLE: Characterization of Novel Breast Cancer Specific Gene,
BCSG1, in Human Breast Cancer Progression (97Breast)

PRINCIPAL INVESTIGATOR: Yiliang Liu, Ph.D.

CONTRACTING ORGANIZATION: Long Island Jewish Medical Center
New Hyde Park, New York 11040

REPORT DATE: July 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010110 048

DTIC QUALITY INSPECTED 3

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE July 1999	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 98 - 30 Jun 99)	
4. TITLE AND SUBTITLE Characterization of Novel Breast Cancer Specific Gene, BCSG1, in Human Breast Cancer Progression (97Breast)		5. FUNDING NUMBERS DAMD17-98-1-8118	
6. AUTHOR(S) Yiliang Liu, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Long Island Jewish Medical Center New Hyde Park, New York 11040		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT <i>(Maximum 200 words)</i> <div style="text-align: center; padding: 10px;"> <p>We recently identified and cloned a novel breast cancer-specific gene BCSG1 by direct differential cDNA sequencing. BCSG1 has a great sequence homology with Alzheimer disease (AD)-related neurotic protein synuclein, and thus was also named as synuclein γ (SNCG). Overexpression of SNCG in breast cancer cells led to a significant increase in motility and invasiveness <i>in vitro</i> and a profound augmentation metastasis <i>in vivo</i>. Our data suggest that the member of neurotic protein synucleins might have important functions outside the central nervous system and play a role in breast cancer progression.</p> </div>			
14. SUBJECT TERMS Breast Cancer		15. NUMBER OF PAGES 12	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓
____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Yi Leung Au 7/26/99
PI - Signature Date

TABLE OF CONTENTS

TABLE OF CONTENTS	1
BACKGROUND AND SIGNIFICANCE	2
WORK ACCOMPLISHED	2
TRAINING	3
REFERENCES	3
APPENDIX	

Cancer Res. reprint (59: 742-747, 1999)

I. BACKGROUND AND SIGNIFICANCE

Identification of quantitative changes in gene expression that occur in the malignant mammary gland, if sufficiently characterized, may yield novel molecular markers which may be useful in the understanding of breast cancer development and progression (1). Within this context, we have previously reported the isolation of differentially expressed genes in the cDNA libraries from normal breast and infiltrating breast cancer using the EST-based differential cDNA sequencing approach (2, 3). Of many putative differentially expressed genes (2, 3), a breast cancer specific gene, BCSG1, which was (a) identified as a group of EST specifically expressed in mammary gland relative to other organs and was (b) high abundance in a breast cancer cDNA library but scarcely in a normal breast cDNA library, was identified as a putative breast cancer specific gene (2).

Interestingly, BCSG1 revealed no homology to any other known growth factors or oncogenes; rather, BCSG1 revealed extensive sequence homology to AD-related neurotic proteins synucleins that are mainly expressed in brain and localized to presynaptic terminals (4-7). The pathological hallmark of AD is amyloid deposition in neurotic plaques and blood vessels (8). Two major intrinsic constituents of amyloid are a 39-43 AA peptide named A β component (8) and the recently identified non-A β component (NAC) (4). NAC precursor was cloned from a human brain library (4) and named synuclein α (SNCA) because it shares 95% sequence homology with rat synuclein. Recently, the second synuclein named synuclein β (SNCB) was cloned from human brain and has 61% identical sequence with SNCA (6). The previously identified BCSG1, which is also highly expressed in brain (2), has 54% and 56% sequence identity with SNCA and SNCB, respectively, and has been renamed as synuclein γ (SNCG) (9). Thus, the previously unrecognized homology between these proteins defines a family of human brain synucleins that currently has three members. Although synucleins are abundant proteins expressed in presynaptic terminals and tightly associated with amyloid plaque in AD and Lewy body in Parkinson's disease (PD) (10), their functions have not been defined yet. SNCA aggregation may be important in the etiology and pathogenesis in neurodegenerative disorders such as AD and PD (10). Being identified as a breast cancer specific gene, we previously demonstrated a stage-specific SNCG expression as follows: SNCG was undetectable in normal or benign breast lesions, showed partial expression in ductal carcinoma *in situ*, but was expressed at an extremely high level in advanced infiltrating breast cancer. In the current studies, the effects of SNCG on breast cancer growth and metastasis were investigated.

II. WORK ACCOMPLISHED

The overall hypothesis to be evaluated is that up-regulation of BCSG1/SNCG expression may indicate breast cancer malignant progression from a benign breast or a low grade *in situ* carcinoma and to a highly infiltrating carcinoma. The overexpression of BCSG1 may correlate with clinical aggressiveness of breast cancers. Therefore an alternations of BCSG1 expression may lead to an abnormal growth and malignant progression.

Overexpression of SNCG in breast cancer cells led to a significant increase in motility and invasiveness *in vitro* and a profound augmentation metastasis *in vivo*. This is the first report indicating the potential involvement of synuclein in the non-neurotic disease. An elucidation of the reasons for SNCG overexpression in infiltrating breast cancer and SNCG-induced metastasis may shed some light on the pathogenesis of not only breast cancer progression but also neurodegenerative disorders. Please see attached paper for detail description.

III. TRAINING

This is PI's first independent grant. The proposed studies of the current grant application includes a variety of different aims and experiments ranging from basic molecular biology, cell biology, in vivo orthotopic nude mice model for tumor growth and metastasis, and a clinical oriented study on screening clinical human breast specimens. This is the first time that PI has a chance to independently carry out a very challenge, yet ambitious, multi display project. During the last year, PI has gained a lot of experience on animal model and in vivo analysis of tumor metastasis. The success on the current grant proposal will encourage and facilitate PI's future career development as an independent clinically oriented breast cancer investigator.

IV. REFERENCES

1. Porter-Jordan, K. and Lippman, M. E. Overview of the biological markers of breast cancer. *Hematol. Oncol. Clin. N. Am.*, 8: 73-100, 1994.
2. Ji, H., Liu, Y. E., Jia, T., Wang, M., Liu, J., Xiao, G., Joseph, B. K., Rosen, C. and Shi, Y. E. Identification of a breast cancer-specific gene, BCSG1, by direct differential complementary DNA sequencing. *Cancer Res.*, 57: 759-764, 1997.
3. Shi, Y.E., Ni, J., Xiao, G., Liu, Y. E., Fuchs, A., Yu, G., Su, J., Cosgrove, J. M., Xing, L., Zhang, M., Li, J., Aggarwal, B. B., Meager, A. and Gentz, R. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. *Cancer Res.*, 57: 3084-3091, 1997.
4. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y. and Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc. Natl. Acad. Sci. U.S.A.*, 90(23): 11282-6 1993.
5. Xia, Y., Rohan-de-Silva, H. A., Rosi, B. L., Yamaoka, L. H., Rimmmler, J. B., Pericak-Vance, M. A., Ross, A. D., Chen, X., Masliah, E., DeTeresa, R., Iwai, A., Sundsmo, M., Thomas, R. G., Hofstetter, C. R., Gregory, E., Hansen, L. A., Katzman, R., Thal, L. J. and Saitoh, T. Genetic studies in Alzheimer's disease with an NACP/a-Synuclein polymorphism. *Ann. Neurol.*, 40: 207-215, 1996.
6. Jakes, R., Spillantini, Maria Grazia and Goedert, Michel. Identification of two distinct synucleins from human brain. *FEBS Letters*, 345: 27-34, 1994.
7. Spillantini, M. G., Schmidt, M.L., Lee, V.M., Trojanowski, J. Q., Jakes, R. and Goedert, M. α - Synuclein in Lewy bodies. *Nature*, 388: 839-840, 1997.
8. Masters, C. L., Simms, G., Wenman, N.A., Multhup, G., McDonald, B. L. and Beyreuther, K. Amyloid plaque core in Alzheimer's disease and Down syndrome. *Proc. Natl. Acad. Sci. USA*, 82: 4245-4249, 1985.
9. Clayton, D. F. and George, J. M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. *Trends Neurosci.*, 21(6): 249-254, 1998.
10. Takeda, A., Mallory, M., Sundsmo, M., Honer W., Hansen, L. and Masliah, E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. *J. Pathol.*, 152(2): 367-372, 1998.

Stimulation of Breast Cancer Invasion and Metastasis by Synuclein γ^1

Tongli Jia, Yiliang E. Liu, Jingwen Liu, and Y. Eric Shi²

Departments of Pediatrics [T. J., Y. E. L., Y. E. S.] and Pathology [Y. E. S.], Long Island Jewish Medical Center, The Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York 11040, and Palo Alto VA Health Care System, Palo Alto, California 94304 [J. L.]

ABSTRACT

We recently identified and cloned novel breast cancer-specific gene *BCSG1* by direct differential cDNA sequencing. *BCSG1* has a great sequence homology with the Alzheimer's disease-related neural protein synuclein (SNC); thus, it was also named SNC- γ . Overexpression of SNC- γ in breast cancer cells leads to a significant increase in motility and invasiveness *in vitro* and a profound augmentation of metastasis *in vivo*. Our data suggest that this member of the neural protein SNCs might have important functions outside the central nervous system and may play a role in breast cancer progression.

INTRODUCTION

If sufficiently characterized, the identification of quantitative changes in gene expression that occur in the malignant mammary gland may yield novel molecular markers that may be useful in understanding breast cancer development and progression (1). Within this context, we have previously reported the isolation of differentially expressed genes in cDNA libraries from normal breast tissue and infiltrating breast cancer using the expressed sequence tag-based differential cDNA sequencing approach (2, 3). Of the many putative differentially expressed genes (2, 3), *BCSG1*, which was identified as a group of expressed sequence tags specifically expressed in the mammary gland relative to other organs and abundantly expressed in a breast cancer cDNA library but scarcely seen in a normal breast cDNA library, was identified as a putative breast cancer-specific gene (2).

Interestingly, *BCSG1* revealed no homology to any other known growth factors or oncogenes; however, *BCSG1* revealed extensive sequence homology to the AD³-related neural proteins called SNCs that are expressed mainly in the brain and localized to presynaptic terminals (4-7). The pathological hallmark of AD is amyloid deposition in neurotic plaques and blood vessels (8). Two major intrinsic constituents of amyloid are a 39-43-amino acid peptide named the A β component (8) and the recently identified non-A β component (4). The non-A β component of the AD precursor was cloned from a human brain library (4) and named SNCA because it shares a 95% sequence homology with rat SNC. Recently, a second SNC named SNCB was cloned from human brain, and it has a 61% sequence identity with SNCA (6). The previously identified *BCSG1*, which is also highly expressed in the brain (2), has a 54 and 56% sequence identity with SNCA and SNCB, respectively, and has been renamed SNCG (9). Thus, the previously unrecognized homology between these proteins defines a family of human brain SNCs that currently

has three members. Although SNCs are abundant proteins expressed in presynaptic terminals and are strongly associated with amyloid plaque in AD and Lewy body in PD (10), their functions have not yet been defined. SNCA aggregation may be important in the etiology and pathogenesis of neurodegenerative disorders such as AD and PD (10). During its identification as a breast cancer-specific gene, we previously demonstrated stage-specific SNCG expression as follows: (a) SNCG was undetectable in normal or benign breast lesions; (b) SNCG showed partial expression in ductal carcinoma *in situ*; and (c) SNCG was expressed at an extremely high level in advanced infiltrating breast cancer. The effects of SNCG on breast cancer growth and metastasis were investigated in the current studies.

MATERIALS AND METHODS

Transfection. Full-length SNCG cDNA was inserted into a pCI-neo mammalian expression vector, and the resulting vector was transfected into MDA-MB-435 cells as described previously (3, 11).

Preparation of CM. All of the clones were maintained in subconfluent monolayers with 10% FCS. The medium was discarded, and the monolayers were washed twice with PBS. The monolayers were cultured in the absence of serum in DMEM supplemented with transferrin (1 mg/liter), fibronectin (1 mg/liter), and trace elements (Biofluids, Rockville, MD). After 24 h, the serum-free medium was discarded, and the cells were replenished with the fresh serum-free medium. The CM were collected 30 h later. Media were then centrifuged at 1,200 \times g, and the supernatants were saved and concentrated approximately 5-fold using an Amicon hollow fiber concentrator with a M_r 10,000 cutoff at 4°C. The protein concentrations of CM were determined and normalized.

MMP Activity. The MMP enzymatic activity of the CM was assayed using a quenched fluorescent substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂ (Bachem) as described previously (12). The CM were pretreated with APMA for activation (13).

In Vitro Invasion and Motility Assay. As described previously (11), cell invasion and motility were analyzed in a modified Boyden chamber assay using 8- μ m polycarbonate membranes coated with 4 mg/ml growth factor-reduced Matrigel.

Tumor Growth in Athymic Nude Mice. A tumorigenic assay was performed in nude mice as described previously (3, 11). Briefly, approximately 0.4×10^6 cells (0.15 ml) were injected into a 5-6-week old female athymic nude mouse (Frederick Cancer Research and Development Center, Frederick, MD). Each animal received two injections, one on each side, in the mammary fat pads between the first and second nipples. Tumor size was determined at weekly intervals by three-dimensional measurements (in millimeters) using a caliper. Only measurable tumors were used to calculate the mean tumor volume for each tumor cell clone at each time point. Animals were sacrificed 32-40 days after injection, when the largest tumors reached about 15 mm in diameter.

Assessment of Regional Lymph Node and Lung Metastasis. As described previously (11), the axillary lymph nodes and lungs of sacrificed animals were excised, weighed, fixed in formalin, embedded in paraffin, and stained with H&E for a microscopic examination for morphological evidence of tumor metastasis. Sections were reviewed and scored by two pathologists.

Antibody Production. The purified synthetic SNCG peptide corresponding to amino acids 101-117 (2) was conjugated and injected into New Zealand rabbits as reported previously (12). The antiserum was purified using SNCG peptide affinity chromatography.

Received 8/24/98; accepted 12/1/98.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by Grant DAMD17-98-8118 from the United States Army Breast Cancer Research Program, Grant RPG-99-028-01-CCE from the American Cancer Society, and Helen and Irving Schneider.

² To whom requests for reprints should be addressed, at Department of Pediatrics, Schneider Children Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11040. Phone: (718) 470-3086; Fax: (718) 470-6744; E-mail: shi@lij.edu.

³ The abbreviations used are: AD, Alzheimer's disease; APMA, *p*-aminophenylmercuric acetate; MAP, microtubule-associated protein; MMP, matrix metalloproteinase; PD, Parkinson's disease; SNC, synuclein; SNCA, SNC- α ; SNCB, SNC- β ; SNCG, SNC- γ ; CM, conditioned media; OM, oncostatin M.




Fig. 1. Transfection of SNCG to MDA-MB-435 cells. A, Northern blot. Each lane contained 30 μ g of total RNA. B, Western blot with an affinity-purified specific SNCG peptide polyclonal antibody. Each lane contained 20 μ g of protein. Lane 1, neo-435-1; Lane 2, SNCG-435-2; Lane 3, SNCG-435-1; Lane 4, SNCG-435-3; Lane 5, neo-435-2.

RESULTS AND DISCUSSION

Transfection of SNCG into MDA-MB-435 Human Breast Cancer Cells. To determine the effects of SNCG on invasion/metastasis, we selected MDA-MB-435 human breast cancer cells as recipients for SNCG-mediated gene transfection due to their lack of detectable SNCG transcript (2) and their highly tumorigenic and aggressive phenotype in nude mice (11). Cells were transfected with a plasmid vector containing a neomycin resistance gene (neo clones) or with the same vector containing full-length SNCG cDNA (SNCG clones). MDA-MB-435 clones expressing SNCG were designated as SNCG-435 clones, and the control neo-transfected cells were designated as neo-435 clones. Fig. 1 shows the Northern blot and Western blot analyses of SNCG expression in selected clones. All selected SNCG-435 clones expressed SNCG mRNA transcripts and proteins. In contrast, none of the neo-435 clones produced any detectable SNCG transcripts and proteins. No changes in morphology were observed in these clones. Based on the level of SNCG expression, we selected SNCG-435-1, SNCG-435-3, neo-435-1, and neo-435-2 clones for the subsequent studies.

In Vitro Growth of SNCG-transfected Cells. To determine whether SNCG overexpression affects the growth of MDA-MB-435 cells, cells from exponentially growing cultures of different MDA-MB-435 clones were seeded in triplicate at 3000 cells/well (24-well plate) in 1 ml of DMEM-5% serum. The growth rates of SNCG-positive SNCG-435-1 and SNCG-435-3 cells were compared with those of SNCG-negative neo-435-1 and neo-435-2 cells in a monolayer culture. No significant differences in growth rate were observed among SNCG-positive and SNCG-negative cells (data not shown).

Metastasis in the Orthotopic Nude Mice Model. Because SNCG was highly expressed in the infiltrating breast cancer cells relative to benign or noninvasive *in situ* carcinomas (2), we were interested in

studying whether SNCG is an instigator of metastasis or merely a correlative product during breast cancer progression. The effect of SNCG expression on metastasis was assayed in an *in vivo* orthotopic (mammary fat pad) nude mouse model. Two independent experiments were done to confirm reproducibility, and the data from these experiments are summarized in Table 1. After a lag phase of 10 days, mice given implants of both SNCG-positive and SNCG-negative cells developed tumors. There was no difference in tumor incidence between neo-435 and SNCG-435 clones. Starting at about 20 days after inoculation, tumor necrosis was observed in tumors derived from SNCG-435-1 and SNCG-435-3 cells. Neo-435-1 and neo-435-2 cells also developed some tumor necrosis, but with less intensity. Consistent with the similar *in vitro* growth rates, there was no significant difference in primary tumor size between the neo-435 and SNCG-435 clones at 40 days after injection.

To study tumor dissemination, axillary lymph nodes and lungs were examined physically at autopsy and then subjected to microscopic examination for morphological evidence of tumor cells by light microscopy on H&E-stained paraffin sections. For the axillary lymph node, the average weight was 15 mg for neo-435 mice and 44 mg for SNCG-435 mice. The increased lymph node weight reflects the invaded breast tumors. Representative H&E-stained sections for neo-435 and SNCG-435 lymph nodes are shown in Fig. 2, A and B. Microscopic examination indicated that SNCG-435-1 and SNCG-435-3 mice showed a significantly higher average lymph node positivity (64 and 77%) compared to that (27%) of SNCG-negative neo-435-1 and neo-435-2 mice (Table 1). For lung metastases, the numbers of visible nodules on the surface of the lungs increased dramatically from an average of 1 for neo-435 mice to an average of 23 for SNCG-435 mice (Table 1). The representative lungs were shown in Fig. 2C. When these lungs were examined microscopically, large numbers of micrometastases were observed in SNCG-435 mice; the lungs of neo-435 mice had significantly fewer micrometastases (data not shown). Representative H&E-stained sections for neo-435 and SNCG-435 lungs are shown in Fig. 2, D-G. To our knowledge, human breast cancer cells usually do not form such a profound regional and metastatic tumor dissemination (visible lung nodules) in the spontaneous mammary fat pad nude mouse model. This dramatic SNCG-stimulated metastasis suggests a role for SNCG as a key positive regulator for breast cancer invasion and metastasis. The overexpression of SNCG in malignant infiltrating breast epithelial cells compared to the low expression level in noninvasive *in situ* carcinoma (2) suggests that SNCG expression is a meaningful marker for breast cancer malignant progression and may signal the more

Table 1 Effects of SNCG on tumor incidence, tumor size, and axillary lymph node and lung metastasis

Cells (400,000) were injected at day 1 into the mammary fat pads, and tumor volumes and lymph node and lung micrometastases were determined. Lymph node metastases were measured by microscopic examination for morphological evidence of tumor cells on the fixed axillary lymph nodes. Lung metastases were measured by the presence of visible tumor nodules on the surface of the lung. Volumes are expressed as the means \pm SEs (number of tumors assayed). Experiment 1 had a total of 16 injections for eight mice in each group, and the mice were killed 42 days after injection. For experiment 2, there was a total of 10 injections for five mice in each group, and the mice were killed 38 days after injection. Statistical comparisons for SNCG-positive clones and SNCG-negative clones showed that there was no significant difference in the mean tumor sizes between pooled SNCG-positive and pooled SNCG-negative tumors. The lymph node positivity of pooled SNCG-435-1 tumors versus combined pooled SNCG-negative neo-435-1 and neo-435-2 tumors was $P < 0.039$ and $P < 0.029$ for pooled SNCG-435-3 tumors versus SNCG-negative tumors. Statistical comparison of primary tumors was analyzed by Student's *t* test. A χ^2 test was used for a statistical analysis of lymph node metastasis.

Experiment	Clones	Volume (cm ³) of the primary tumor	Tumor incidence	Lymph node	Lymph node	Lung metastasis
			Tumor total (%)	Average weight (mg)	No. positive/total no.	No. of nodules
1	neo-435-1	1.74 \pm 0.52	16/16 (100)	14	3/16 (19)	0
	neo-435-2	1.9 \pm 0.31	14/16 (88)	18	4/15 (27)	2
	SNCG-435-1	1.45 \pm 0.37	15/16 (94)	43	10/15 (67)	19
	SNCG-435-3	1.78 \pm 0.31	16/16 (100)	50	12/16 (75)	31
2	neo-435-1	1.35 \pm 0.39	9/10 (90)	12	3/10 (30)	1
	neo-435-2	1.69 \pm 0.44	10/10 (100)	15	3/9 (33)	1
	SNCG-435-1	1.73 \pm 0.45	10/10 (100)	45	6/10 (60)	24
	SNCG-435-3	1.49 \pm 0.34	10/10 (100)	39	7/9 (78)	17




Fig. 2. Axillary lymph nodes and lung metastasis from neo-435 mice and SNCG-435 mice. The mice were sacrificed at day 40 after cell injection. Lymph nodes and lungs were isolated, and some were subjected to H&E staining. Representative axillary lymph nodes from a neo-435-1 mouse (A) and a SNCG-435-3 mouse (B) are shown. *Arrow*, an invasive breast tumor that mainly occupied the lymph node in a SNCG-435-3 mouse. A and B, $\times 10$. C, representative lung metastases from mice injected with SNCG-positive and SNCG-negative cells. The *left lung* was from a neo-435-1 mouse, and the *right lung* was from a SNCG-435-3 mouse. The metastatic tumors only reflect the nodules on the surface of the lungs ($\times 2.5$). D-G, microscopic examination of representative lung metastases in H&E-stained sections. D, a lung without metastases from a neo-435-1 mouse. E, a lung with micrometastases from a neo-435-2 mouse. F, a lung with a small breast tumor nodule from a SNCG-435-1 mouse. G, a lung with a large breast tumor nodule from a SNCG-435-3 mouse. *Arrows*, breast tumors or cancer cells. D-G, $\times 20$.




Fig. 3. Analysis of the MMP activities of SNCG-positive and SNCG-negative cells. The pooled CM from SNCG-negative neo-435-1 and neo-435-2 cells and SNCG-positive SNCG-435-1 and SNCG-435-3 cells were collected, concentrated 5-fold, normalized for protein concentrations, and subjected to MMP activity analysis. Recombinant AMPA-activated MMP-2 (80 ng) was used as a positive control. All values were normalized to the enzymatic activity of the recombinant MMP-2, which was taken as 100%. The numbers represent the means \pm SD of three tests.

advanced invasive/metastatic phenotype of human breast cancer. In this regard, the up-regulation of SNCG expression may facilitate breast cancer progression leading to metastasis.

MMP Activity. In an effort to investigate the molecular mechanisms underlying SNCG-induced metastasis, we studied several invasion-related factors, including MMP and cell motility. The amyloid protein has recently been demonstrated to be a strong stimulator of MMP-2 and MMP-9 expression in astrocytes (14). It is well established that the overproduction and unrestrained activity of MMPs, particularly MMP-2 and MMP-9, are linked to the malignant conversion of a variety of different tumor cells (15–22) including mammary tumors (18–22). It is interesting to test whether SNCG, an amyloid-related protein, stimulates MMP-2 and MMP-9 expression in breast cancer cells and leads to the more metastatic phenotype. We investigated whether SNCG overexpression would increase MMP activity in MDA-MB-435 cells. In this regard, the pooled CM from two SNCG-negative cells and the pooled CM from two SNCG-positive cells were concentrated and subjected to a MMP enzymatic assay. As shown in Fig. 3, no significant differences in the basal levels of proteolytic activities were observed between neo-435 and SNCG-435 clones. Mammalian MMPs are usually secreted as latent proenzymes (zymogen) and require activation for their enzymatic activity. The incubation of CM with the MMP activator organomercurial compound APMA resulted in an approximately 2-fold increase in proteolytic activity for the CM from both neo-435 and SNCG-435 clones. However, no significant difference in APMA-activated MMP activities was observed between neo-435 and SNCG-435 clones. Because the measured enzymatic activity represents the net MMP activity, reflecting the balance between activated MMPs and the tissue inhibitors of metalloproteinase, our data suggest that SNCG-induced metastasis may not be mediated by the regulation of MMP and tissue inhibitors of metalloproteinase.

Stimulation of Invasiveness and Motility of MDA-MB-435 Cells by SNCG.

We used an *in vitro* reconstituted basement membrane (Matrigel) invasion assay to determine the effect of SNCG on cell invasion. All three SNCG-negative cells (parental MDA-MB-435, neo-435-1, and neo-435-2) were moderately invasive. At the end of a 48-h incubation, an average of approximately 250 SNCG-negative cells had crossed the Matrigel barrier. A significant stimulation of invasiveness was noted in two SNCG-positive clones, with a 3-fold increase for SNCG-435-1 cells and a 4.3-fold increase for SNCG-435-3 cells (Fig. 4A). We also investigated the effect of SNCG on cell migration without Matrigel. A similar SNCG-stimulated pattern of migration was observed. At the end of a 24-h incubation, SNCG-435-1 cells migrated 4-fold, and SNCG-435-3 cells migrated 4.2-fold over that of average SNCG-negative cells (Fig. 4B). The similar magnitude of the invasion-stimulating and migration-stimulating activity of SNCG suggests that the increased invasion in SNCG clones may be mediated by an alteration of cell motility. To determine whether the increased cell motility is mediated by chemotaxis due to the different concentrations of serum or chemoattractants in the top and bottom chambers, we compared the migration of SNCG-435-3 and neo-435-1 cells under three different culture conditions: (a) serum-free conditions; (b) serum with gradient; and (c) serum without gradient. As shown in Fig. 5, although the migration was relatively




Fig. 4. Stimulation of invasiveness and migration of MDA-MB-435 cells by SNCG. Cells were seeded at a density of 30,000 cells/ml/well on 8- μ m polycarbonate membranes coated with (A) or without (B) 4 mg/ml growth factor-reduced Matrigel. The top chamber contained 5% FCS, and the bottom chamber contained 10% FCS. A, after incubation in a humidified incubator with 5% CO₂ at 37°C for 48 h, the medium and cells were removed from the bottom chambers and counted using a microscope. B, cells were cultured under the same conditions as described in A. The number of cells that migrated was counted after a 24-h incubation. All values were expressed as the number of invaded cells. The numbers represent the means \pm SD of three cultures.




Fig. 5. Comparison of the cell migration of SNCG-435-3 and neo-435-1 cells under different conditions. Cells were cultured on noncoated membrane at a density of 30,000 cells/ml/well. The cells that migrated were harvested at 32 h after incubation. A, 0% serum in both the top and bottom chambers. B, 2% serum in both the top and bottom chambers. C, 2% serum in the top chamber and 10% serum in the bottom chamber. All values were expressed as the number of invaded cells. The numbers represent the means \pm SD of triplet wells.

low under serum-free conditions, there was a 2.8-fold increase in migration in SNCG-435-3 cells compared with that in neo-435-1 cells. When 2% serum was added in the top chamber, the migration of both SNCG-positive and -negative cells increased significantly. However, the migration of SNCG-435-3 cells was not affected by the serum gradient. Approximately 1600 of the SNCG-435-3 cells that migrated into the bottom chamber contained either 2% serum or 10% serum. These data suggest that the increased migration in SNCG-positive cells is not likely to be mediated by chemotaxis but rather by high motility features intrinsic to the cells.

Many breast tumors go through a series of events from the time of initial detection to the formation of the lethal invasive and metastatic stage. According to the three-step hypothesis of invasion (23), cell adhesion, local proteolysis, and subsequent migration or motility are key steps in the traversal of the basement membrane and connective tissue. In this study, we provide evidence linking the overexpression of neural protein SNCG, a previously identified breast cancer-specific gene (2), in human breast cancer cells with increased motility and invasive activity *in vitro* and a profound augmentation of metastasis *in vivo*.

SNCG proteins have a structural resemblance to apolipoproteins but are abundant in the neuronal cytosol and are present in enriched amounts at presynaptic terminals (9). SNCs have been specifically implicated in two diseases: AD and PD. In AD patients, a peptide derived from SNCA forms an intrinsic component of plaque amyloid (9). In PD patients, a SNCA allele is genetically linked to several independent familial cases, and the protein appears to accumulate in Lewy bodies (9). The general significance of the involvement of neural protein SNCG in cancer metastasis is unknown. Recently, SNCA and SNCB were identified as two abundant proteins through their reactivity with a monoclonal antibody recognizing MAP- τ (6) on immunoblots. In eukaryotic cells, microtubules, actin, and intermedi-

ate filaments interact to form the cytoskeletal network involved in the determination of cell architecture, mitosis, differentiation, and motility (24). Cytoskeletal organization and dynamics depend on protein self-associations and interactions with regulatory elements such as MAPs. There is increasing evidence that MAPs, including MAP- τ , play a critical role in inducing microtubule assembly and controlling the dynamic instability of microtubules, thus controlling the state of their assembly and organization in cells (reviewed in Ref. 24). SNCG may interact with MAPs and regulate the cytoskeletal organization and dynamics, leading to increased motility. Nevertheless, our data indicate that the increased expression of SNCG correlates with breast cancer progression (2) and leads to a more malignant metastatic phenotype. We also demonstrated that SNCG expression in breast cancer cells was subjected to cytokine regulation and dramatically suppressed by the tumor growth inhibitor OM, and that this OM-induced transcriptional suppression of the SNCG gene was associated with OM-mediated growth inhibition.⁴ OM is an antitumor cytokine produced mainly by activated T cells and macrophages (25), and its growth-suppressing activity has been well studied in breast cancer cells (26–28). One characteristic of the host response to tumor progression is the infiltration of tumors by macrophages and T lymphocytes. The production of tumor-suppressing cytokines in a timely and locally (*in situ*) released fashion may represent an important function of the host defense system in suppressing tumor progression. From this prospective view, the dramatic suppression of SNCG expression in malignant breast cells by OM may represent the host-mediated tumor suppression leading to the inhibition of breast cancer progression.

This is the first report indicating the potential involvement of SNC in a non-neural disease. An elucidation of the reasons for SNCG overexpression in infiltrating breast cancer and SNCG-induced metastasis may shed some light on the pathogenesis of breast cancer progression as well as neurodegenerative disorders.

REFERENCES

- Porter-Jordan, K., and Lippman, M. E. Overview of the biological markers of breast cancer. *Hematol. Oncol. Clin. N. Am.*, **8**: 73–100, 1994.
- Ji, H., Liu, Y. E., Jia, T., Wang, M., Liu, J., Xiao, G., Joseph, B. K., Rosen, C., and Shi, Y. E. Identification of a breast cancer-specific gene, *BCSG1*, by direct differential complementary DNA sequencing. *Cancer Res.*, **57**: 759–764, 1997.
- Shi, Y. E., Ni, J., Xiao, G., Liu, Y. E., Fuchs, A., Yu, G., Su, J., Cosgrove, J. M., Xing, L., Zhang, M., Li, J., Aggarwal, B. B., Meager, A., and Gentz, R. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, *MRG*. *Cancer Res.*, **57**: 3084–3091, 1997.
- Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc. Natl. Acad. Sci. USA*, **90**: 11282–11286, 1993.
- Xia, Y., Rohan-de-Silva, H. A., Rosi, B. L., Yamaoka, L. H., Rimpler, J. B., Pericak-Vance, M. A., Ross, A. D., Chen, X., Masliah, E., DeTeresa, R., Iwai, A., Sundsmo, M., Thomas, R. G., Hofstetter, C. R., Gregory, E., Hansen, L. A., Katzman, R., Thal, L. J., and Saitoh, T. Genetic studies in Alzheimer's disease with an NACP/ α -synuclein polymorphism. *Ann. Neurol.*, **40**: 207–215, 1996.
- Jakes, R., Spillantini, M. G., and Goedert, M. Identification of two distinct synucleins from human brain. *FEBS Lett.*, **345**: 27–34, 1994.
- Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. α -Synuclein in Lewy bodies. *Nature (Lond.)*, **388**: 839–840, 1997.
- Masters, C. L., Simms, G., Wenman, N. A., Multhup, G., McDonald, B. L., and Beyreuther, K. Amyloid plaque core in Alzheimer's disease and Down syndrome. *Proc. Natl. Acad. Sci. USA*, **82**: 4245–4249, 1985.
- Clayton, D. F., and George, J. M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. *Trends Neurosci.*, **21**: 249–254, 1998.
- Takeda, A., Mallory, M., Sundsmo, M., Honer W., Hansen, L., and Masliah, E. Abnormal accumulation of NACP/ α -synuclein in neurodegenerative disorders. *J. Pathol.*, **152**: 367–372, 1998.

⁴ J. Liu, M. J. Spence, Y. L. Zhang, T. Jia, Y. E. Liu, and Y. E. Shi. Transcriptional suppression of breast cancer-specific SNCG expression by the growth-inhibitory cytokine OM, submitted for publication.

11. Wang, M., Liu, Y. E., John, G., Sheng, S., Fuchs, F., Rosen, E. M., and Shi, Y. E. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. *Oncogene*, *14*: 2767-2774, 1997.
12. Liu, Y. E., Wang, M., Greene, J., Su, J., Ullrich, S., Sheng, S., Alexander, P., Sang, Q. A., and Shi, Y. E. Preparation and characterization of recombinant TIMP-4 protein. *J. Biol. Chem.*, *272*: 20479-20483, 1997.
13. Shi, Y. E., Torri, J., Yieh, L., Wellstein, A., Lippman, M. E., and Dickson, R. B. Isolation and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. *Cancer Res.*, *53*: 1409-1415, 1993.
14. Deb, S., and Gottschall, P. E. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with β -amyloid peptides. *J. Neurochem.*, *66*: 1641-1647, 1996.
15. Pyke, C., Ralfkiaer, E., Tryggvason, K., and Dano, K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. *Am. J. Pathol.*, *142*: 359-365, 1993.
16. Naylor, M. S., Stamp, G. W., Davies, B. D., and Balkwill, F. R. Expression and activity of MMPs and their regulators in ovarian cancer. *Int. J. Cancer*, *58*: 50-56, 1994.
17. Polette, M., Clavel, C., Birembaut, P., and De-Clerck, Y. A. Localization by *in situ* hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. *Pathol. Res. Pract.*, *189*: 1052-1057, 1993.
18. Urbanski, S. J., Edwards, D. R., Maitland, A., Leco, K. J., Watson, A., and Kossakowska, A. E. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. *Br. J. Cancer*, *66*: 1188-1194, 1992.
19. Tryggvason, K., Hoyhtya, M., and Pyke, C. Type IV collagenases in invasive tumors. *Breast Cancer Res. Treat.*, *24*: 209-218, 1993.
20. Polette, M., Clavel, C., Cockett, M., Girod-de-Bentzmann, S., Murphy, G., and Birembaut, P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. *Invasion Metastasis*, *13*: 31-37, 1993.
21. Basset, P., Wolf, C., Rouyer, N., Bellocq, J. P., Rio, M. C., and Chambon, P. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. *Cancer (Phila.)*, *74*: 1045-1049, 1994.
22. Heppner, K. J., Matrisian, L. M., Jensen, R. A., and Rodgers, W. H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. *Am. J. Pathol.*, *149*: 273-282, 1996.
23. Stettler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. *Annu. Rev. Cell Biol.*, *9*: 541-573, 1993.
24. Maccioni, R. B., and Cambiazo, V. Role of microtubule-associated proteins in the control of microtubule assembly. *Physiol. Rev.*, *75*: 835-865, 1995.
25. Zading, J. M., Shoyab, M., Marquardt, H., Hanson, M., Lioubin, M. N., and Tdaro, G. J. Oncostatin M: a growth regulator produced by differentiated lymphoma cells. *Proc. Natl. Acad. Sci. USA*, *83*: 9739-9743, 1986.
26. Liu, J., Spence, M. J., Wallace, P. M., Forcier, K., Hellstrom, I., and Vestal, R. E. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the *c-myc* proto-oncogene. *Cell Growth Differ.*, *8*: 667-676, 1997.
27. Spence, M. J., Vestal, R. E., and Liu, J. Oncostatin M-mediated transcriptional suppression of the *c-myc* gene in breast cancer cells. *Cancer Res.*, *57*: 2223-2228, 1997.
28. Douglas, A. M., Grant, S. L., Goss, G. A., Clouston, D. R., Sutherland, R. L., and Begley, C. G. Oncostatin M induces the differentiation of breast cancer cells. *Int. J. Cancer*, *75*: 64-73, 1998.